POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER).
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle. |
| Excretion | Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion. |
| Half-life | The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism. |
| Protein binding | Potassium is not significantly protein-bound (<10%). Dextrose has negligible protein binding. No specific binding proteins identified for potassium; it exists as free ion in plasma. |
| Volume of Distribution | Potassium Vd is approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid. Total body potassium is ~50 mEq/kg, with 98% intracellular. The clinical meaning: initial dose distributes into ECF before equilibrating with ICF; rapid IV administration can cause transient hyperkalemia. |
| Bioavailability | Intravenous administration yields 100% bioavailability. Oral potassium chloride has ~90-100% bioavailability, but this formulation is not for oral use. Dextrose only given IV; not applicable for oral. |
| Onset of Action | Intravenous infusion produces immediate physiological effects, with ECG changes (e.g., T-wave normalization) occurring within minutes. Onset for potassium repletion depends on infusion rate; typically 30-60 minutes for measurable serum K+ increase. |
| Duration of Action | After cessation of IV infusion, serum potassium declines rapidly within 2-4 hours due to redistribution and renal clearance. The dextrose effect on glucose utilization lasts 1-2 hours post-infusion. Continuous infusion is needed for sustained repletion. |
Intravenous infusion; typical adult dose: 10-20 mEq per hour, not exceeding 40 mEq per dose and 200 mEq per day, titrated based on serum potassium and ECG monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-50 mL/min: reduce infusion rate by 25%; GFR 15-29: reduce rate by 50%; GFR <15: avoid use or use with extreme caution at reduced rate, monitor potassium closely. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor serum potassium and acid-base status closely in hepatic impairment due to risk of hyperkalemia. |
| Pediatric use | Intravenous infusion; 0.5-1 mEq/kg per dose, maximum 40 mEq per dose, infused at rate not exceeding 0.5-1 mEq/kg/hour; adjust based on serum potassium and clinical response. |
| Geriatric use | Use lower initial infusion rates (e.g., 5-10 mEq/hour) due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER).
| Breastfeeding | Potassium chloride and dextrose are normal constituents of breast milk. Supplementation does not significantly alter milk composition. No adverse effects in nursing infants expected. M/P ratio not applicable as substances are endogenous. |
| Teratogenic Risk | No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No increased risk of congenital anomalies reported. However, maternal hyperkalemia or severe hypoglycemia may indirectly affect fetal well-being. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can lead to cardiac arrest.
| Serious Effects |
["Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal failure with oliguria or azotemia","Concurrent use of potassium-sparing diuretics (unless under close monitoring)","Acidosis (may worsen hyperkalemia)","Crush injury or massive hemolysis (risk of acute hyperkalemia)","Addison's disease (untreated)"]
| Precautions | ["Risk of hyperkalemia, especially in patients with renal impairment","Cardiac monitoring recommended during infusion","Avoid rapid intravenous administration","Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders","May cause phlebitis at injection site"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium, glucose, electrolytes, and fluid balance during infusion. Fetal heart rate monitoring indicated if maternal condition unstable or if potassium administered for critical indications. |
| Fertility Effects | No known adverse effects on fertility from potassium chloride or dextrose at therapeutic doses. |